Pieris, AstraZeneca ink $45m deal for inhaled respiratory drugs

Pieris Pharmaceuticals (NSDQ:PIRS) inked a $45 million deal with AstraZeneca (NYSE:AZN) to develop a group of inhaled drugs for respiratory diseases.

According to the deal, Pieris will get $45 million up front to bring an experimental asthma drug into human clinical trials. The drug is slated to begin Phase I testing this year, which will bring the company another $12.5 million. AstraZeneca plans to fund the development of that program and up to 4 other drugs for respiratory diseases.

Get the full story at our sister site, Drug Delivery Business News.

The post Pieris, AstraZeneca ink $45m deal for inhaled respiratory drugs appeared first on MassDevice.

from MassDevice http://ift.tt/2pZbvxa